Key Takeaways
- • AusperBio Therapeutics closed a $120 million Series C financing round, bringing total capital raised since 2024 to $360 million, demonstrating sustained institutional investor confidence in the company's oligonucleotide platform.
- • The round was led by a strategic investor with participation from RA Capital Management, L.P., a new investor, alongside continued backing from existing investors HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments.
- • AusperBio is a near-commercial biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for chronic hepatitis B (CHB) and other disease indications, positioning itself in a differentiated therapeutic space.
- • The financing reflects investor conviction in AusperBio's lead programs and proprietary oligonucleotide technology platform, with the company approaching clinical commercialization milestones.
Summary
AusperBio Therapeutics, Inc. and its subsidiary Ausper Biopharma Co., Ltd., announced the closing of a $120 million Series C financing round, marking a significant milestone in the company's development trajectory toward commercialization. The financing round reflects sustained confidence among institutional investors in the company's therapeutic approach and platform technology.
The round was anchored by a leading strategic investor, with newly participating investor RA Capital Management, L.P., joining the syndicate. The financing also secured continued support from AusperBio's existing investor base, including HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. This mix of strategic and financial investors indicates broad-based conviction across multiple investor categories regarding the company's commercial potential.
Since 2024, AusperBio has successfully raised $360 million across its financing rounds, substantially positioning the company with capital resources typically associated with near-commercial biopharmaceutical enterprises. The company's focus on developing targeted oligonucleotide therapeutics for chronic hepatitis B represents entry into a well-defined therapeutic market segment. The sustained capital inflows and expanded investor participation signal confidence in both AusperBio's lead programs and the differentiated nature of its oligonucleotide technology platform, suggesting the company has achieved meaningful validation of its clinical and commercial strategy among sophisticated institutional investors.
The round was anchored by a leading strategic investor, with newly participating investor RA Capital Management, L.P., joining the syndicate. The financing also secured continued support from AusperBio's existing investor base, including HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. This mix of strategic and financial investors indicates broad-based conviction across multiple investor categories regarding the company's commercial potential.
Since 2024, AusperBio has successfully raised $360 million across its financing rounds, substantially positioning the company with capital resources typically associated with near-commercial biopharmaceutical enterprises. The company's focus on developing targeted oligonucleotide therapeutics for chronic hepatitis B represents entry into a well-defined therapeutic market segment. The sustained capital inflows and expanded investor participation signal confidence in both AusperBio's lead programs and the differentiated nature of its oligonucleotide technology platform, suggesting the company has achieved meaningful validation of its clinical and commercial strategy among sophisticated institutional investors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.